MIRM Mirum Pharmaceuticals Inc
Company Analysis
Latest News
🔴 Mirum Pharmaceuticals is trading 4.1% down today alongside biotech weakness; no clear company-specific catalyst
Mirum Pharmaceuticals is trading at $82.55, down 4.08%, alongside broader biotech weakness; however, no clear company-specific catalyst was identified. - XBI...
Mirum Pharmaceuticals Announces Positive Phase 3 LIVMARLI Data for Cholestatic Liver Diseases
Mirum Pharmaceuticals announced positive topline results from its Phase 3 EXPAND study for LIVMARLI (maralixibat) in treating cholestatic pruritus (itchiness)...
🔴 Mirum Pharmaceuticals is trading 4% down
Mirum Pharmaceuticals is trading at $82.56, down 4.01%; no reliable report links the decline to the study data. - The company announcement confirms an October...
🟢 Mirum Pharmaceuticals is trading 4.15% up in pre-market ahead of Oct. 12, 2026 results call
Mirum Pharmaceuticals is trading at $89.58, up 4.15%, ahead of an investor call on topline Phase 3 EXPAND results. - The call is scheduled for October 12,...
🟢 Mirum Pharmaceuticals is trading 5.5% up today after RBC raised its target to $155
Mirum Pharmaceuticals is trading higher after RBC Capital raised its price target to $155 from $135, with shares at $85.85 (+5.53%) on October 9, 2026. - RBC...
🟢 Mirum Pharmaceuticals is trading 4.3% up today
Mirum Pharmaceuticals is trading at $82.66, up +4.30%, with the cause of the October 7 move unclear. - No verified company announcement or other clear...
🔴 Mirum Pharmaceuticals is trading 4% down with no identified catalyst
Mirum Pharmaceuticals is trading 4.0% down now at $78.17, with no specific catalyst identified; broader biotech weakness may be contributing. - No...
Mirum Pharmaceuticals Gets $195 Target After Positive Phase 3 HDV Data
H.C. Wainwright raised its price target for Mirum Pharmaceuticals to $195 from $140 and maintained a Buy rating. The move followed positive topline results...
MIRM Announces FDA Approval for Atebrioz and Positive Phase 3 Data for Brelovitug
Mirum Pharmaceuticals announced two significant pipeline updates: the U.S. FDA approval of Atebrioz™ (zilurgisertib) for fibrodysplasia ossificans progressiva...
🔴 Mirum Pharmaceuticals is trading 4.1% down with no verified company-specific catalyst
Mirum Pharmaceuticals is trading 4.06% down at $86.06, with no verified company-specific announcement explaining the decline. - The company had scheduled a...
Bank of America Buys $65.8 Million Mirum Stake, Defying Insider Sales
Bank of America Corp DE acquired 561,724 shares of Mirum Pharmaceuticals for approximately $65.8 million. This purchase represents a 0.87% ownership stake in...
🔴 Mirum Pharmaceuticals is trading 4.03% down today — no fresh company-specific catalyst identified
Mirum Pharmaceuticals is trading 4.03% down at $94.84, with no fresh company-specific announcement or clearly reported September 18, 2026 catalyst...
🟢 Mirum Pharmaceuticals is trading 4.1% up today after conference presentations highlighted strong LIVMARLI sales
Mirum Pharmaceuticals is trading 4.1% up now at $97.77, following investor presentations at the H.C. Wainwright conference on September 15 and a scheduled...
🟢 Mirum Pharmaceuticals is trading 5% up today in pre-market with no clear catalyst
Mirum Pharmaceuticals is trading 4.84% up now at $105.50, with no new company-specific announcement identified for September 4, 2026. - Latest major catalyst...